Trial Outcomes & Findings for A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults (NCT NCT03201419)

NCT ID: NCT03201419

Last Updated: 2022-03-02

Results Overview

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits. Level estimated for baseline value of mean number of nocturnal voids equal to 2, and 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval are presented in this endpoint.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

302 participants

Primary outcome timeframe

Baseline, during 12 weeks of treatment

Results posted on

2022-03-02

Participant Flow

A total of 71 sites were authorized to recruit subjects for the trial between July 2017 and July 2019. The trial sites that screened subjects to the trial were: 5 in Belgium, 10 in Canada, 5 in Czech Republic, 2 in Germany, 5 in Hungary, 1 in Poland and 43 in the Unites States of America (USA).

A total of 1721 subjects were screened, wherein, 531 met the eligibility criteria and entered the enrichment period. Of these, 302 subjects met the eligibility criteria at Visit (V) 4 (randomization), and were randomized to treatment with FE 201836 (different doses), placebo, or desmopressin. A total of 278 subjects completed the trial.

Participant milestones

Participant milestones
Measure
FE 201836 500 µg (Randomized Treatment Period)
FE 201836 500 µg oral solution and placebo orally disintegrating tablet (ODT), administered once daily
FE 201836 350 µg (Randomized Treatment Period)
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 µg (Randomized Treatment Period)
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 µg (Randomized Treatment Period)
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 µg (Randomized Treatment Period)
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 µg (Randomized Treatment Period)
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
Placebo oral solution and placebo ODT, administered once daily
Desmopressin 25 µg (Randomized Treatment Period)
Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)
Desmopressin 50 µg (Randomized Treatment Period)
Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)
Overall Study
STARTED
60
27
24
14
13
34
87
26
17
Overall Study
COMPLETED
52
24
22
14
12
33
81
25
15
Overall Study
NOT COMPLETED
8
3
2
0
1
1
6
1
2

Reasons for withdrawal

Reasons for withdrawal
Measure
FE 201836 500 µg (Randomized Treatment Period)
FE 201836 500 µg oral solution and placebo orally disintegrating tablet (ODT), administered once daily
FE 201836 350 µg (Randomized Treatment Period)
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 µg (Randomized Treatment Period)
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 µg (Randomized Treatment Period)
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 µg (Randomized Treatment Period)
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 µg (Randomized Treatment Period)
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
Placebo oral solution and placebo ODT, administered once daily
Desmopressin 25 µg (Randomized Treatment Period)
Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)
Desmopressin 50 µg (Randomized Treatment Period)
Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)
Overall Study
Adverse Event
3
1
0
0
1
1
5
0
0
Overall Study
Lost to Follow-up
1
0
0
0
0
0
0
0
0
Overall Study
Protocol Deviation
0
0
0
0
0
0
1
0
0
Overall Study
Withdrawal by Subject
4
2
1
0
0
0
0
1
2
Overall Study
Other
0
0
1
0
0
0
0
0
0

Baseline Characteristics

Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
FE 201836 500 µg (Randomized Treatment Period)
n=60 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 µg (Randomized Treatment Period)
n=27 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 µg (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 µg (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 µg (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 µg (Randomized Treatment Period)
n=34 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=87 Participants
Placebo oral solution and placebo ODT, administered once daily
Desmopressin 25µg (Randomized Treatment Period)
n=26 Participants
Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)
Desmopressin 50 µg (Randomized Treatment Period)
n=17 Participants
Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)
Total
n=302 Participants
Total of all reporting groups
Age, Continuous
59.0 years
STANDARD_DEVIATION 14.1 • n=60 Participants
58.0 years
STANDARD_DEVIATION 14.3 • n=27 Participants
60.8 years
STANDARD_DEVIATION 13.0 • n=24 Participants
63.9 years
STANDARD_DEVIATION 7.5 • n=14 Participants
61.5 years
STANDARD_DEVIATION 9.2 • n=13 Participants
59.1 years
STANDARD_DEVIATION 10.4 • n=34 Participants
58.9 years
STANDARD_DEVIATION 13.9 • n=87 Participants
51.1 years
STANDARD_DEVIATION 11.1 • n=26 Participants
60.9 years
STANDARD_DEVIATION 9.5 • n=17 Participants
58.8 years
STANDARD_DEVIATION 12.8 • n=302 Participants
Age, Customized
<65 years old
35 years
n=60 Participants
19 years
n=27 Participants
14 years
n=24 Participants
6 years
n=14 Participants
6 years
n=13 Participants
21 years
n=34 Participants
52 years
n=87 Participants
24 years
n=26 Participants
11 years
n=17 Participants
188 years
n=302 Participants
Age, Customized
>=65 years old
25 years
n=60 Participants
8 years
n=27 Participants
10 years
n=24 Participants
8 years
n=14 Participants
7 years
n=13 Participants
13 years
n=34 Participants
35 years
n=87 Participants
2 years
n=26 Participants
6 years
n=17 Participants
114 years
n=302 Participants
Sex: Female, Male
Female
40 Participants
n=60 Participants
18 Participants
n=27 Participants
16 Participants
n=24 Participants
5 Participants
n=14 Participants
8 Participants
n=13 Participants
16 Participants
n=34 Participants
51 Participants
n=87 Participants
26 Participants
n=26 Participants
0 Participants
n=17 Participants
180 Participants
n=302 Participants
Sex: Female, Male
Male
20 Participants
n=60 Participants
9 Participants
n=27 Participants
8 Participants
n=24 Participants
9 Participants
n=14 Participants
5 Participants
n=13 Participants
18 Participants
n=34 Participants
36 Participants
n=87 Participants
0 Participants
n=26 Participants
17 Participants
n=17 Participants
122 Participants
n=302 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
17 Participants
n=59 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
9 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
6 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
3 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
7 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
12 Participants
n=34 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
35 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
12 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
4 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
105 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
Ethnicity (NIH/OMB)
Not Hispanic or Latino
42 Participants
n=59 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
18 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
18 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
11 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
6 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
22 Participants
n=34 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
51 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
14 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
13 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
195 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=59 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=34 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
0 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=60 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
1 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
1 Participants
n=33 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
1 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
3 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
Race (NIH/OMB)
Asian
2 Participants
n=60 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=33 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
2 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
1 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
5 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=60 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=33 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
Race (NIH/OMB)
Black or African American
6 Participants
n=60 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
3 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
2 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
1 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
1 Participants
n=33 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
5 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
6 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
4 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
28 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
Race (NIH/OMB)
White
52 Participants
n=60 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
24 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
22 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
14 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
11 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
31 Participants
n=33 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
78 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
19 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
13 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
264 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
Race (NIH/OMB)
More than one race
0 Participants
n=60 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=33 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=60 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=27 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=24 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=14 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=13 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=33 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=86 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=26 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=17 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
0 Participants
n=300 Participants • Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.
Baseline body mass index (BMI)
30.66 kg/m^2
STANDARD_DEVIATION 6.05 • n=60 Participants
29.91 kg/m^2
STANDARD_DEVIATION 4.64 • n=27 Participants
29.56 kg/m^2
STANDARD_DEVIATION 6.50 • n=24 Participants
32.03 kg/m^2
STANDARD_DEVIATION 8.26 • n=14 Participants
31.52 kg/m^2
STANDARD_DEVIATION 4.60 • n=13 Participants
30.93 kg/m^2
STANDARD_DEVIATION 6.16 • n=34 Participants
29.54 kg/m^2
STANDARD_DEVIATION 5.14 • n=87 Participants
31.89 kg/m^2
STANDARD_DEVIATION 7.99 • n=26 Participants
31.05 kg/m^2
STANDARD_DEVIATION 6.49 • n=17 Participants
30.44 kg/m^2
STANDARD_DEVIATION 6.00 • n=302 Participants
Mean Number of Nocturnal Voids
2.88 nocturnal voids
STANDARD_DEVIATION 0.84 • n=59 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
3.01 nocturnal voids
STANDARD_DEVIATION 0.72 • n=27 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
3.10 nocturnal voids
STANDARD_DEVIATION 1.11 • n=24 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
2.98 nocturnal voids
STANDARD_DEVIATION 0.84 • n=14 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
3.33 nocturnal voids
STANDARD_DEVIATION 0.82 • n=13 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
3.24 nocturnal voids
STANDARD_DEVIATION 1.18 • n=34 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
3.09 nocturnal voids
STANDARD_DEVIATION 0.83 • n=86 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
3.38 nocturnal voids
STANDARD_DEVIATION 1.45 • n=25 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
3.16 nocturnal voids
STANDARD_DEVIATION 1.22 • n=17 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
3.09 nocturnal voids
STANDARD_DEVIATION 0.98 • n=299 Participants • Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.
Mean Nocturnal Urine Volume (NUV)
804.6 mL
STANDARD_DEVIATION 313.8 • n=58 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
766.0 mL
STANDARD_DEVIATION 242.1 • n=26 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
897.3 mL
STANDARD_DEVIATION 373.6 • n=24 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
803.1 mL
STANDARD_DEVIATION 304.7 • n=14 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
892.4 mL
STANDARD_DEVIATION 206.7 • n=13 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
879.9 mL
STANDARD_DEVIATION 354.1 • n=34 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
752.3 mL
STANDARD_DEVIATION 269.5 • n=86 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
839.3 mL
STANDARD_DEVIATION 286.4 • n=25 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
803.5 mL
STANDARD_DEVIATION 425.8 • n=17 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
808.8 mL
STANDARD_DEVIATION 307.5 • n=297 Participants • Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.
Mean Nocturnal Polyuria Index
48.87 percentage
STANDARD_DEVIATION 12.04 • n=55 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
46.76 percentage
STANDARD_DEVIATION 10.08 • n=25 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
49.75 percentage
STANDARD_DEVIATION 15.96 • n=22 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
50.99 percentage
STANDARD_DEVIATION 12.93 • n=14 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
44.59 percentage
STANDARD_DEVIATION 6.58 • n=12 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
47.01 percentage
STANDARD_DEVIATION 9.86 • n=31 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
47.91 percentage
STANDARD_DEVIATION 14.29 • n=76 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
49.21 percentage
STANDARD_DEVIATION 13.93 • n=23 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
49.10 percentage
STANDARD_DEVIATION 17.93 • n=16 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
48.24 percentage
STANDARD_DEVIATION 12.99 • n=274 Participants • Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.
Mean Nocturia Impact (NI) Diary Total Score
47.20 score on a scale
STANDARD_DEVIATION 18.39 • n=60 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
47.03 score on a scale
STANDARD_DEVIATION 28.44 • n=26 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
38.76 score on a scale
STANDARD_DEVIATION 19.09 • n=24 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
36.28 score on a scale
STANDARD_DEVIATION 22.10 • n=14 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
51.63 score on a scale
STANDARD_DEVIATION 17.73 • n=13 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
42.46 score on a scale
STANDARD_DEVIATION 23.28 • n=32 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
47.66 score on a scale
STANDARD_DEVIATION 21.25 • n=86 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
58.06 score on a scale
STANDARD_DEVIATION 20.78 • n=25 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
39.88 score on a scale
STANDARD_DEVIATION 23.08 • n=17 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
46.30 score on a scale
STANDARD_DEVIATION 21.81 • n=297 Participants • Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.
Mean NI Diary Overall Impact Score
59.2 score on a scale
STANDARD_DEVIATION 25.4 • n=60 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
62.3 score on a scale
STANDARD_DEVIATION 29.8 • n=26 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
55.9 score on a scale
STANDARD_DEVIATION 21.6 • n=24 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
53.0 score on a scale
STANDARD_DEVIATION 30.6 • n=14 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
68.6 score on a scale
STANDARD_DEVIATION 20.7 • n=13 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
59.9 score on a scale
STANDARD_DEVIATION 26.8 • n=32 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
62.7 score on a scale
STANDARD_DEVIATION 26.8 • n=86 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
71.5 score on a scale
STANDARD_DEVIATION 23.8 • n=25 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
54.2 score on a scale
STANDARD_DEVIATION 28.0 • n=17 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
61.2 score on a scale
STANDARD_DEVIATION 26.3 • n=297 Participants • Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.
Insomnia Severity Index (ISI)
15.8 score on a scale
STANDARD_DEVIATION 5.4 • n=55 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
15.7 score on a scale
STANDARD_DEVIATION 6.1 • n=26 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
14.3 score on a scale
STANDARD_DEVIATION 5.1 • n=24 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
13.0 score on a scale
STANDARD_DEVIATION 6.7 • n=14 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
16.4 score on a scale
STANDARD_DEVIATION 5.6 • n=9 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
14.7 score on a scale
STANDARD_DEVIATION 4.8 • n=31 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
15.6 score on a scale
STANDARD_DEVIATION 5.8 • n=77 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
18.2 score on a scale
STANDARD_DEVIATION 4.7 • n=26 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
15.5 score on a scale
STANDARD_DEVIATION 6.8 • n=17 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.
15.6 score on a scale
STANDARD_DEVIATION 5.6 • n=279 Participants • Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.

PRIMARY outcome

Timeframe: Baseline, during 12 weeks of treatment

Population: The intention-to-treat analysis set for the randomized treatment period (ITT-RT) comprised of all the subjects randomized at Visit 4.

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits. Level estimated for baseline value of mean number of nocturnal voids equal to 2, and 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval are presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=60 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=34 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=87 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment
-1.06 nocturnal voids
Interval -1.28 to -0.86
-0.99 nocturnal voids
Interval -1.2 to -0.78
-0.89 nocturnal voids
Interval -1.12 to -0.69
-0.80 nocturnal voids
Interval -1.0 to -0.62
-0.77 nocturnal voids
Interval -0.97 to -0.59
-0.76 nocturnal voids
Interval -0.95 to -0.58
-0.76 nocturnal voids
Interval -0.95 to -0.58

SECONDARY outcome

Timeframe: Baseline, Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2. MMRM=Mixed Model for Repeated Measurements. For all visit-specific results, the tables present the number of subjects with an observation of the endpoints in question at the specific visit. All secondary analyses are performed using the observed-case approach based on repeated measurements for all subjects in the ITT-RT population. That is, these secondary analyses are based on all subjects with at least one non-missing post-baseline observation (with a baseline value if relevant).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=54 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=33 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=80 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean Number of Nocturnal Voids at Week 1
-0.714 nocturnal voids
Interval -1.005 to -0.424
-1.162 nocturnal voids
Interval -1.577 to -0.747
-0.722 nocturnal voids
Interval -1.149 to -0.296
-0.520 nocturnal voids
Interval -1.058 to 0.017
-0.722 nocturnal voids
Interval -1.318 to -0.126
-0.325 nocturnal voids
Interval -0.709 to 0.059
-0.575 nocturnal voids
Interval -0.842 to -0.308

SECONDARY outcome

Timeframe: Baseline, Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=50 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=76 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean Number of Nocturnal Voids at Week 4
-1.078 nocturnal voids
Interval -1.345 to -0.811
-1.330 nocturnal voids
Interval -1.708 to -0.952
-0.784 nocturnal voids
Interval -1.181 to -0.386
-0.471 nocturnal voids
Interval -0.969 to 0.028
-0.952 nocturnal voids
Interval -1.469 to -0.435
-0.518 nocturnal voids
Interval -0.866 to -0.171
-0.912 nocturnal voids
Interval -1.152 to -0.673

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=44 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=30 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=70 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean Number of Nocturnal Voids at Week 8
-1.085 nocturnal voids
Interval -1.394 to -0.776
-1.177 nocturnal voids
Interval -1.603 to -0.751
-0.965 nocturnal voids
Interval -1.414 to -0.516
-0.490 nocturnal voids
Interval -1.037 to 0.058
-1.077 nocturnal voids
Interval -1.671 to -0.484
-0.786 nocturnal voids
Interval -1.187 to -0.386
-0.953 nocturnal voids
Interval -1.233 to -0.672

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=40 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=19 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=19 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=29 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=69 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean Number of Nocturnal Voids at Week 12
-1.256 nocturnal voids
Interval -1.568 to -0.944
-1.120 nocturnal voids
Interval -1.558 to -0.683
-0.850 nocturnal voids
Interval -1.301 to -0.4
-0.674 nocturnal voids
Interval -1.206 to -0.142
-1.053 nocturnal voids
Interval -1.65 to -0.456
-0.921 nocturnal voids
Interval -1.317 to -0.524
-0.957 nocturnal voids
Interval -1.237 to -0.677

SECONDARY outcome

Timeframe: Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% in the reduction mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=54 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=33 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=80 Participants
Placebo oral solution and placebo ODT, administered once daily
Responder Rate in Nocturnal Voids at Week 1
0.844 odd of response
Interval 0.457 to 1.558
1.202 odd of response
Interval 0.51 to 2.833
0.682 odd of response
Interval 0.28 to 1.662
0.818 odd of response
Interval 0.269 to 2.49
0.810 odd of response
Interval 0.24 to 2.738
0.513 odd of response
Interval 0.227 to 1.157
0.480 odd of response
Interval 0.272 to 0.848

SECONDARY outcome

Timeframe: Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=50 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=76 Participants
Placebo oral solution and placebo ODT, administered once daily
Responder Rate in Nocturnal Voids at Week 4
1.199 odd of response
Interval 0.633 to 2.27
5.851 odd of response
Interval 1.511 to 22.65
0.634 odd of response
Interval 0.255 to 1.575
0.534 odd of response
Interval 0.165 to 1.731
1.760 odd of response
Interval 0.47 to 6.596
0.683 odd of response
Interval 0.301 to 1.55
1.235 odd of response
Interval 0.686 to 2.224

SECONDARY outcome

Timeframe: Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=44 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=30 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=70 Participants
Placebo oral solution and placebo ODT, administered once daily
Responder Rate in Nocturnal Voids at Week 8
1.395 odd of response
Interval 0.717 to 2.715
3.398 odd of response
Interval 1.15 to 10.043
1.928 odd of response
Interval 0.721 to 5.155
0.877 odd of response
Interval 0.286 to 2.688
1.039 odd of response
Interval 0.302 to 3.569
1.489 odd of response
Interval 0.638 to 3.474
1.503 odd of response
Interval 0.806 to 2.803

SECONDARY outcome

Timeframe: Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=40 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=19 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=19 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=29 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=69 Participants
Placebo oral solution and placebo ODT, administered once daily
Responder Rate in Nocturnal Voids at Week 12
3.914 odd of response
Interval 1.83 to 8.37
1.891 odd of response
Interval 0.693 to 5.163
1.824 odd of response
Interval 0.694 to 4.795
0.854 odd of response
Interval 0.279 to 2.611
1.400 odd of response
Interval 0.401 to 4.893
1.395 odd of response
Interval 0.611 to 3.181
1.590 odd of response
Interval 0.844 to 2.993

SECONDARY outcome

Timeframe: During 12 weeks of treatment

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

Defined as 50% reduction in nocturnal voids from baseline. Estimated odds of at least 50% reduction in the aggregated mean number of nocturnal voids for a subject with 2 nocturnal voids at baseline are presented in this endpoint. The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=60 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=34 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=87 Participants
Placebo oral solution and placebo ODT, administered once daily
Responder Rate in Nocturnal Voids During 12 Weeks of Treatment
1.129 odd of response
Interval 0.808 to 1.753
1.095 odd of response
Interval 0.772 to 1.661
1.032 odd of response
Interval 0.711 to 1.543
0.934 odd of response
Interval 0.597 to 1.378
0.887 odd of response
Interval 0.555 to 1.253
0.849 odd of response
Interval 0.534 to 1.187
0.834 odd of response
Interval 0.514 to 1.18

SECONDARY outcome

Timeframe: Baseline, Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall quality of life (QoL) impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items.Responses are scored from 0 to 4 (lowest t o highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=55 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=83 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NI Diary Total Score at Week 1
-7.55 score on a scale
Interval -11.67 to -3.43
-21.91 score on a scale
Interval -28.15 to -15.68
-10.90 score on a scale
Interval -17.17 to -4.63
-8.93 score on a scale
Interval -17.15 to -0.72
-9.68 score on a scale
Interval -18.41 to -0.94
-8.75 score on a scale
Interval -14.27 to -3.23
-8.07 score on a scale
Interval -11.48 to -4.65

SECONDARY outcome

Timeframe: Baseline, Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=53 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=78 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NI Diary Total Score at Week 4
-12.62 score on a scale
Interval -16.89 to -8.35
-17.44 score on a scale
Interval -23.8 to -11.08
-14.37 score on a scale
Interval -20.96 to -7.78
-11.23 score on a scale
Interval -19.82 to -2.65
-22.23 score on a scale
Interval -31.11 to -13.35
-13.29 score on a scale
Interval -19.0 to -7.58
-14.20 score on a scale
Interval -17.77 to -10.64

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=50 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=30 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=79 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NI Diary Total Score at Week 8
-16.03 score on a scale
Interval -20.49 to -11.57
-23.22 score on a scale
Interval -29.79 to -16.64
-15.10 score on a scale
Interval -21.85 to -8.35
-12.04 score on a scale
Interval -20.77 to -3.32
-19.23 score on a scale
Interval -28.62 to -9.83
-14.11 score on a scale
Interval -20.0 to -8.22
-14.83 score on a scale
Interval -18.5 to -11.16

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=50 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=77 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NI Diary Total Score at Week 12
-16.92 score on a scale
Interval -21.66 to -12.18
-24.44 score on a scale
Interval -31.52 to -17.35
-14.68 score on a scale
Interval -21.94 to -7.42
-10.13 score on a scale
Interval -19.37 to -0.88
-22.59 score on a scale
Interval -32.46 to -12.71
-17.18 score on a scale
Interval -23.39 to -10.96
-17.45 score on a scale
Interval -21.36 to -13.53

SECONDARY outcome

Timeframe: Baseline, during 12 weeks of treatment

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the mean over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits. Level estimated for baseline value of mean NI Diary Total Score equal to 40 is presented in this endpoint. The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=60 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=34 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=87 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Aggregated Mean NI Diary Total Score During 12 Weeks of Treatment
-12.40 score on a scale
Interval -14.71 to -8.59
-12.69 score on a scale
Interval -15.07 to -10.53
-12.75 score on a scale
Interval -15.16 to -10.57
-12.77 score on a scale
Interval -15.21 to -10.59
-12.77 score on a scale
Interval -15.23 to -10.54
-12.78 score on a scale
Interval -15.18 to -10.5
-12.77 score on a scale
Interval -15.18 to -10.47

SECONDARY outcome

Timeframe: During 12 weeks of treatment

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The percentages of nights during the treatment period with at most one nocturnal void are presented in this endpoint. Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=58 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=33 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=84 Participants
Placebo oral solution and placebo ODT, administered once daily
Percentage of Nights With at Most One Nocturnal Void During 12 Weeks of Treatment
67.2 percentage of nights
Interval 58.2 to 76.2
77.5 percentage of nights
Interval 64.9 to 90.2
64.5 percentage of nights
Interval 51.0 to 78.0
55.3 percentage of nights
Interval 38.3 to 72.3
73.2 percentage of nights
Interval 55.1 to 91.2
61.4 percentage of nights
Interval 49.3 to 73.5
62.0 percentage of nights
Interval 53.8 to 70.2

SECONDARY outcome

Timeframe: During 12 weeks of treatment

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The percentages of nights during the treatment period with complete response, i.e. no nocturnal voids are presented in this endpoint. Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=58 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=33 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=84 Participants
Placebo oral solution and placebo ODT, administered once daily
Percentage of Nights With No Nocturnal Voids During 12 Weeks of Treatment
23.3 percentage of nights
Interval 16.3 to 30.3
28.8 percentage of nights
Interval 19.0 to 38.6
17.3 percentage of nights
Interval 6.8 to 27.8
12.9 percentage of nights
Interval -0.3 to 26.1
14.8 percentage of nights
Interval 0.8 to 28.8
21.5 percentage of nights
Interval 12.1 to 30.9
23.0 percentage of nights
Interval 16.6 to 29.4

SECONDARY outcome

Timeframe: Baseline, Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=55 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=83 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NI Diary Overall Impact Score at Week 1
-10.98 score on a scale
Interval -16.4 to -5.56
-30.39 score on a scale
Interval -38.62 to -22.17
-15.51 score on a scale
Interval -23.85 to -7.17
-11.77 score on a scale
Interval -22.69 to -0.85
-2.79 score on a scale
Interval -14.29 to 8.7
-12.26 score on a scale
Interval -19.57 to -4.95
-13.46 score on a scale
Interval -17.89 to -9.03

SECONDARY outcome

Timeframe: Baseline, Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=53 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=78 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NI Diary Overall Impact Score at Week 4
-22.17 score on a scale
Interval -28.25 to -16.09
-26.07 score on a scale
Interval -35.09 to -17.05
-19.35 score on a scale
Interval -28.8 to -9.9
-18.36 score on a scale
Interval -30.66 to -6.07
-17.95 score on a scale
Interval -30.5 to -5.41
-21.40 score on a scale
Interval -29.54 to -13.26
-21.75 score on a scale
Interval -26.74 to -16.77

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=50 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=30 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=79 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NI Diary Overall Impact Score at Week 8
-28.13 score on a scale
Interval -34.76 to -21.5
-34.97 score on a scale
Interval -44.69 to -25.25
-21.71 score on a scale
Interval -31.8 to -11.62
-19.03 score on a scale
Interval -32.06 to -6.0
-23.84 score on a scale
Interval -37.71 to -9.96
-20.70 score on a scale
Interval -29.45 to -11.94
-25.32 score on a scale
Interval -30.69 to -19.95

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=50 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=77 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NI Diary Overall Impact Score at Week 12
-30.47 score on a scale
Interval -37.49 to -23.45
-36.76 score on a scale
Interval -47.18 to -26.34
-20.84 score on a scale
Interval -31.65 to -10.02
-15.32 score on a scale
Interval -29.1 to -1.54
-28.89 score on a scale
Interval -43.4 to -14.39
-27.13 score on a scale
Interval -36.35 to -17.91
-30.03 score on a scale
Interval -35.74 to -24.33

SECONDARY outcome

Timeframe: Baseline, during 12 weeks of treatment

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits. Level estimated for baseline value of mean NI Diary Overall Impact Score equal to 40 is presented in this endpoint. The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=60 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=34 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=87 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Aggregated Mean NI Diary Overall Impact Score During 12 Weeks of Treatment
-6.50 score on a scale
Interval -10.57 to -2.85
-6.25 score on a scale
Interval -9.78 to -3.03
-6.11 score on a scale
Interval -9.49 to -2.9
-6.00 score on a scale
Interval -9.28 to -2.7
-5.98 score on a scale
Interval -9.29 to -2.58
-5.97 score on a scale
Interval -9.32 to -2.57
-5.96 score on a scale
Interval -9.42 to -2.49

SECONDARY outcome

Timeframe: Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse). Visit-specific PGI-I in urinary symptoms is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=53 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=33 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=81 Participants
Placebo oral solution and placebo ODT, administered once daily
Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 1
2.475 score on a scale
Interval 2.261 to 2.689
2.045 score on a scale
Interval 1.723 to 2.367
2.708 score on a scale
Interval 2.385 to 3.031
2.786 score on a scale
Interval 2.363 to 3.209
2.781 score on a scale
Interval 2.316 to 3.245
2.758 score on a scale
Interval 2.482 to 3.033
2.745 score on a scale
Interval 2.571 to 2.919

SECONDARY outcome

Timeframe: Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse). Visit-specific PGI-I in urinary symptoms is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=53 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=20 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=30 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=77 Participants
Placebo oral solution and placebo ODT, administered once daily
Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 4
2.121 score on a scale
Interval 1.866 to 2.376
2.191 score on a scale
Interval 1.813 to 2.569
2.447 score on a scale
Interval 2.039 to 2.855
2.521 score on a scale
Interval 1.995 to 3.047
2.385 score on a scale
Interval 1.859 to 2.91
2.582 score on a scale
Interval 2.244 to 2.921
2.596 score on a scale
Interval 2.386 to 2.806

SECONDARY outcome

Timeframe: Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse). Visit-specific PGI-I in urinary symptoms is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=49 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=28 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=78 Participants
Placebo oral solution and placebo ODT, administered once daily
Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 8
1.843 score on a scale
Interval 1.572 to 2.113
1.887 score on a scale
Interval 1.493 to 2.281
2.528 score on a scale
Interval 2.109 to 2.947
2.286 score on a scale
Interval 1.761 to 2.811
2.155 score on a scale
Interval 1.587 to 2.723
2.273 score on a scale
Interval 1.917 to 2.629
2.573 score on a scale
Interval 2.355 to 2.791

SECONDARY outcome

Timeframe: Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse). Visit-specific PGI-I in urinary symptoms is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=46 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=18 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=72 Participants
Placebo oral solution and placebo ODT, administered once daily
Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 12
1.667 score on a scale
Interval 1.357 to 1.977
1.671 score on a scale
Interval 1.224 to 2.119
2.656 score on a scale
Interval 2.167 to 3.146
2.452 score on a scale
Interval 1.855 to 3.049
1.678 score on a scale
Interval 1.052 to 2.304
2.384 score on a scale
Interval 1.994 to 2.774
2.490 score on a scale
Interval 2.24 to 2.74

SECONDARY outcome

Timeframe: Baseline, Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe). Change from baseline in visit-specific PGI-S is presented in this endpoint. Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=53 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=10 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=28 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=80 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Patient Global Impression of Severity (PGI-S) Scores at Week 1
-0.739 score on a scale
Interval -0.927 to -0.552
-0.970 score on a scale
Interval -1.253 to -0.688
-0.811 score on a scale
Interval -1.094 to -0.529
-0.643 score on a scale
Interval -1.012 to -0.273
-0.417 score on a scale
Interval -0.84 to 0.007
-0.719 score on a scale
Interval -0.984 to -0.454
-0.593 score on a scale
Interval -0.746 to -0.44

SECONDARY outcome

Timeframe: Baseline, Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe). Change from baseline in visit-specific PGI-S is presented in this endpoint. Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=52 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=20 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=75 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in PGI-S Scores at Week 4
-0.837 score on a scale
Interval -1.015 to -0.659
-1.025 score on a scale
Interval -1.292 to -0.758
-0.798 score on a scale
Interval -1.081 to -0.516
-0.749 score on a scale
Interval -1.115 to -0.383
-0.656 score on a scale
Interval -1.033 to -0.278
-0.936 score on a scale
Interval -1.189 to -0.684
-0.898 score on a scale
Interval -1.045 to -0.75

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe). Change from baseline in visit-specific PGI-S is presented in this endpoint. Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=48 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=25 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=76 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in PGI-S Scores at Week 8
-1.132 score on a scale
Interval -1.322 to -0.942
-1.410 score on a scale
Interval -1.688 to -1.132
-0.825 score on a scale
Interval -1.114 to -0.536
-0.643 score on a scale
Interval -1.004 to -0.281
-0.816 score on a scale
Interval -1.215 to -0.418
-1.013 score on a scale
Interval -1.279 to -0.747
-0.800 score on a scale
Interval -0.953 to -0.647

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe). Change from baseline in visit-specific PGI-S is presented in this endpoint. Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=45 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=18 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=70 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in PGI-S Scores at Week 12
-1.181 score on a scale
Interval -1.383 to -0.979
-1.338 score on a scale
Interval -1.63 to -1.045
-0.894 score on a scale
Interval -1.208 to -0.579
-0.638 score on a scale
Interval -1.02 to -0.257
-1.168 score on a scale
Interval -1.571 to -0.764
-1.041 score on a scale
Interval -1.312 to -0.77
-0.853 score on a scale
Interval -1.016 to -0.69

SECONDARY outcome

Timeframe: Baseline, Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely). Change from baseline in visit-specific Hsu Bother is presented in this endpoint. Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=50 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=9 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=30 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=70 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Hsu 5-point Likert Bother Scale at Week 1
-0.649 score on a scale
Interval -0.922 to -0.376
-1.072 score on a scale
Interval -1.441 to -0.703
-0.748 score on a scale
Interval -1.125 to -0.37
-0.458 score on a scale
Interval -0.942 to 0.026
-0.346 score on a scale
Interval -0.955 to 0.262
-0.376 score on a scale
Interval -0.714 to -0.039
-0.570 score on a scale
Interval -0.799 to -0.341

SECONDARY outcome

Timeframe: Baseline, Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely). Change from baseline in visit-specific Hsu Bother is presented in this endpoint. Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=47 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=8 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=68 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Hsu 5-point Likert Bother Scale at Week 4
-0.896 score on a scale
Interval -1.161 to -0.63
-0.940 score on a scale
Interval -1.294 to -0.586
-0.712 score on a scale
Interval -1.083 to -0.34
-0.606 score on a scale
Interval -1.079 to -0.132
-1.096 score on a scale
Interval -1.698 to -0.493
-0.861 score on a scale
Interval -1.193 to -0.53
-0.665 score on a scale
Interval -0.885 to -0.445

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely). Change from baseline in visit-specific Hsu Bother is presented in this endpoint. Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=40 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=7 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=71 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Hsu 5-point Likert Bother Scale at Week 8
-0.972 score on a scale
Interval -1.273 to -0.672
-1.044 score on a scale
Interval -1.423 to -0.664
-0.991 score on a scale
Interval -1.389 to -0.594
-0.499 score on a scale
Interval -1.001 to 0.004
-1.012 score on a scale
Interval -1.691 to -0.333
-0.881 score on a scale
Interval -1.24 to -0.522
-0.731 score on a scale
Interval -0.968 to -0.495

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely). Change from baseline in visit-specific Hsu Bother is presented in this endpoint. Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=45 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=8 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=28 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=67 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Hsu 5-point Likert Bother Scale at Week 12
-0.992 score on a scale
Interval -1.306 to -0.679
-1.249 score on a scale
Interval -1.663 to -0.834
-0.700 score on a scale
Interval -1.132 to -0.267
-0.880 score on a scale
Interval -1.416 to -0.343
-0.974 score on a scale
Interval -1.676 to -0.272
-0.921 score on a scale
Interval -1.303 to -0.54
-0.769 score on a scale
Interval -1.027 to -0.511

SECONDARY outcome

Timeframe: Baseline, Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia). Change from baseline in visit-specific ISI is presented in this endpoint. Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=47 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=8 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=68 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in ISI at Week 4
-6.589 score on a scale
Interval -8.046 to -5.133
-6.652 score on a scale
Interval -8.689 to -4.616
-5.630 score on a scale
Interval -7.772 to -3.487
-5.428 score on a scale
Interval -8.2 to -2.656
-4.510 score on a scale
Interval -7.996 to -1.023
-6.372 score on a scale
Interval -8.291 to -4.452
-5.277 score on a scale
Interval -6.493 to -4.061

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia). Change from baseline in visit-specific ISI is presented in this endpoint. Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=40 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=7 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=28 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=71 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in ISI at Week 8
-7.643 score on a scale
Interval -9.14 to -6.147
-8.091 score on a scale
Interval -10.116 to -6.067
-6.693 score on a scale
Interval -8.799 to -4.588
-6.959 score on a scale
Interval -9.668 to -4.25
-5.707 score on a scale
Interval -9.283 to -2.131
-7.167 score on a scale
Interval -9.055 to -5.28
-6.408 score on a scale
Interval -7.603 to -5.213

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia). Change from baseline in visit-specific ISI is presented in this endpoint. Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=45 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=8 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=67 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in ISI at Week 12
-7.807 score on a scale
Interval -9.427 to -6.188
-9.329 score on a scale
Interval -11.619 to -7.04
-6.355 score on a scale
Interval -8.733 to -3.977
-6.193 score on a scale
Interval -9.195 to -3.191
-5.002 score on a scale
Interval -8.865 to -1.138
-7.908 score on a scale
Interval -10.016 to -5.8
-6.678 score on a scale
Interval -8.018 to -5.338

SECONDARY outcome

Timeframe: Baseline, Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occured. The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=54 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=33 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=80 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean Duration of First Undisturbed Sleep Period (FUSP) at Week 1
122.9 minutes
Interval 86.2 to 159.7
187.0 minutes
Interval 132.3 to 241.7
106.0 minutes
Interval 49.6 to 162.4
91.7 minutes
Interval 18.7 to 164.8
82.9 minutes
Interval 2.5 to 163.4
51.3 minutes
Interval 3.9 to 98.7
81.1 minutes
Interval 50.8 to 111.4

SECONDARY outcome

Timeframe: Baseline, Week 4

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred. The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=50 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=22 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=31 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=76 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean Duration of FUSP at Week 4
164.5 minutes
Interval 127.9 to 201.0
211.0 minutes
Interval 156.3 to 265.7
132.3 minutes
Interval 75.2 to 189.4
89.5 minutes
Interval 15.1 to 163.9
122.0 minutes
Interval 46.8 to 197.3
95.5 minutes
Interval 48.6 to 142.5
150.2 minutes
Interval 120.4 to 180.0

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred. The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=44 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=23 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=21 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=12 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=30 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=70 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean Duration of FUSP at Week 8
160.4 minutes
Interval 112.4 to 208.3
225.4 minutes
Interval 157.9 to 293.0
190.2 minutes
Interval 118.9 to 261.6
136.8 minutes
Interval 48.3 to 225.4
163.2 minutes
Interval 68.7 to 257.8
164.3 minutes
Interval 104.9 to 223.7
161.0 minutes
Interval 122.6 to 199.5

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred. The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=40 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=19 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=19 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=29 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=69 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean Duration of FUSP at Week 12
178.5 minutes
Interval 132.5 to 224.5
160.0 minutes
Interval 93.3 to 226.6
180.7 minutes
Interval 112.2 to 249.2
111.5 minutes
Interval 29.7 to 193.2
141.1 minutes
Interval 51.3 to 230.9
166.2 minutes
Interval 110.5 to 221.8
162.8 minutes
Interval 126.9 to 198.7

SECONDARY outcome

Timeframe: Baseline, During 12 Weeks of Treatment

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred. The visit-specific means were aggregated into a mean of current and preceding visits. Level estimated for baseline value of mean duration of FUSP (minutes) equal to 180 is presented in this endpoint. The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=60 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=27 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=13 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=34 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=87 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Aggregated Mean Duration of FUSP During 12 Weeks of Treatment
154.98 minutes
Interval 130.41 to 189.1
150.23 minutes
Interval 130.2 to 181.15
145.95 minutes
Interval 128.21 to 170.9
140.74 minutes
Interval 120.51 to 160.16
139.19 minutes
Interval 117.86 to 157.42
138.13 minutes
Interval 115.62 to 157.24
137.45 minutes
Interval 114.12 to 157.3

SECONDARY outcome

Timeframe: Baseline, Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The nocturnal diuresis rate (mL/min) is calculated as the mean of the nocturnal diuresis for each of the three nights, with the single-night nocturnal diuresis calculated as the ratio of NUV to total time in bed. Change from baseline in visit-specific mean nocturnal diuresis (mL/min) is presented. Level estimated for baseline value of mean nocturnal diuresis (mL/min) equal to 1.3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=53 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=32 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=78 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 1
-0.575 mL/min
Interval -0.687 to -0.463
-0.635 mL/min
Interval -0.801 to -0.468
-0.610 mL/min
Interval -0.779 to -0.44
-0.459 mL/min
Interval -0.678 to -0.239
-0.523 mL/min
Interval -0.766 to -0.28
-0.328 mL/min
Interval -0.474 to -0.182
-0.402 mL/min
Interval -0.494 to -0.31

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The nocturnal diuresis rate (mL/min) is calculated as the mean of the nocturnal diuresis for each of the three nights, with the single-night nocturnal diuresis calculated as the ratio of NUV to total time in bed. Change from baseline in visit-specific mean nocturnal diuresis (mL/min) is presented. Level estimated for baseline value of mean nocturnal diuresis (mL/min) equal to 1.3 is presented in this endpoint.

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=35 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=18 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=18 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=29 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=68 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 12
-0.648 mL/min
Interval -0.789 to -0.508
-0.606 mL/min
Interval -0.805 to -0.408
-0.735 mL/min
Interval -0.937 to -0.533
-0.458 mL/min
Interval -0.693 to -0.223
-0.685 mL/min
Interval -0.945 to -0.425
-0.651 mL/min
Interval -0.812 to -0.49
-0.515 mL/min
Interval -0.619 to -0.412

SECONDARY outcome

Timeframe: Baseline, Week 1

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep including the first void within 30 minutes of rising in the morning. The NUV at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NUV are estimated using a baseline value of 750 (mL).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=53 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=24 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=32 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=78 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NUV in Week 1
-328.8 mL
Interval -395.3 to -262.3
-371.8 mL
Interval -470.4 to -273.3
-352.4 mL
Interval -452.8 to -252.1
-265.5 mL
Interval -395.5 to -135.6
-312.6 mL
Interval -455.9 to -169.3
-218.2 mL
Interval -304.9 to -131.6
-241.6 mL
Interval -296.3 to -186.9

SECONDARY outcome

Timeframe: Baseline, Week 12

Population: The ITT-RT comprised of all the subjects randomized at Visit 4.

The NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep including the first void within 30 minutes of rising in the morning. The NUV at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NUV are estimated using a baseline value of 750 (mL).

Outcome measures

Outcome measures
Measure
FE 201836 500 ug (Randomized Treatment Period)
n=35 Participants
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 ug (Randomized Treatment Period)
n=18 Participants
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 ug (Randomized Treatment Period)
n=18 Participants
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 ug (Randomized Treatment Period)
n=14 Participants
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 ug (Randomized Treatment Period)
n=11 Participants
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 ug (Randomized Treatment Period)
n=29 Participants
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=68 Participants
Placebo oral solution and placebo ODT, administered once daily
Change From Baseline in Mean NUV at Week 12
-367.3 mL
Interval -447.1 to -287.5
-392.4 mL
Interval -505.2 to -279.5
-411.3 mL
Interval -526.0 to -296.7
-284.2 mL
Interval -418.4 to -149.9
-393.5 mL
Interval -541.9 to -245.1
-403.2 mL
Interval -495.5 to -310.9
-317.8 mL
Interval -377.1 to -258.5

Adverse Events

FE 201836 500 µg (Enrichment Period)

Serious events: 2 serious events
Other events: 0 other events
Deaths: 0 deaths

FE 201836 500 µg (Randomized Treatment Period)

Serious events: 1 serious events
Other events: 16 other events
Deaths: 0 deaths

FE 201836 350 µg (Randomized Treatment Period)

Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths

FE 201836 250 µg (Randomized Treatment Period)

Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths

FE 201836 150 µg (Randomized Treatment Period)

Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths

FE 201836 100 µg (Randomized Treatment Period)

Serious events: 1 serious events
Other events: 5 other events
Deaths: 0 deaths

FE 201836 50 µg (Randomized Treatment Period)

Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths

Placebo (Randomized Treatment Period)

Serious events: 2 serious events
Other events: 16 other events
Deaths: 0 deaths

Desmopressin 25 µg (Randomized Treatment Period)

Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths

Desmopressin 50 µg (Randomized Treatment Period)

Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
FE 201836 500 µg (Enrichment Period)
n=531 participants at risk
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 500 µg (Randomized Treatment Period)
n=60 participants at risk
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 µg (Randomized Treatment Period)
n=27 participants at risk
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 µg (Randomized Treatment Period)
n=24 participants at risk
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 µg (Randomized Treatment Period)
n=14 participants at risk
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 µg (Randomized Treatment Period)
n=13 participants at risk
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 µg (Randomized Treatment Period)
n=34 participants at risk
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=87 participants at risk
Placebo oral solution and placebo ODT, administered once daily
Desmopressin 25 µg (Randomized Treatment Period)
n=26 participants at risk
Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)
Desmopressin 50 µg (Randomized Treatment Period)
n=17 participants at risk
Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)
Metabolism and nutrition disorders
Hyponatraemia
0.38%
2/531 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
0.19%
1/531 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Gastrointestinal disorders
Abdominal pain upper
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.7%
1/13 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Gastrointestinal disorders
Colitis
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Immune system disorders
Serum sickness-like reaction
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.7%
1/60 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Infections and infestations
Gastroenteritis
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Infections and infestations
Staphylococcal infection
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.7%
1/27 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Infections and infestations
Urinary tract infection
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.7%
1/27 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.7%
1/27 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.7%
1/27 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Nervous system disorders
Syncope
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
4.2%
1/24 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Skin and subcutaneous tissue disorders
Pruritus
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Skin and subcutaneous tissue disorders
Urticaria
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Injury, poisoning and procedural complications
Facial bones fracture
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
4.2%
1/24 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Injury, poisoning and procedural complications
Subdural haematoma
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
4.2%
1/24 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.

Other adverse events

Other adverse events
Measure
FE 201836 500 µg (Enrichment Period)
n=531 participants at risk
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 500 µg (Randomized Treatment Period)
n=60 participants at risk
FE 201836 500 µg oral solution and placebo ODT, administered once daily
FE 201836 350 µg (Randomized Treatment Period)
n=27 participants at risk
FE 201836 350 µg oral solution and placebo ODT, administered once daily
FE 201836 250 µg (Randomized Treatment Period)
n=24 participants at risk
FE 201836 250 µg oral solution and placebo ODT, administered once daily
FE 201836 150 µg (Randomized Treatment Period)
n=14 participants at risk
FE 201836 150 µg oral solution and placebo ODT, administered once daily
FE 201836 100 µg (Randomized Treatment Period)
n=13 participants at risk
FE 201836 100 µg oral solution and placebo ODT, administered once daily
FE 201836 50 µg (Randomized Treatment Period)
n=34 participants at risk
FE 201836 50 µg oral solution and placebo ODT, administered once daily
Placebo (Randomized Treatment Period)
n=87 participants at risk
Placebo oral solution and placebo ODT, administered once daily
Desmopressin 25 µg (Randomized Treatment Period)
n=26 participants at risk
Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)
Desmopressin 50 µg (Randomized Treatment Period)
n=17 participants at risk
Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)
Blood and lymphatic system disorders
Anaemia
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.7%
1/60 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.7%
1/13 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.9%
1/34 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Ear and labyrinth disorders
Vertigo
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.9%
1/34 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.8%
1/26 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 3 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Gastrointestinal disorders
Nausea
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.0%
3/60 • Number of events 3 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.7%
1/27 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
8.3%
2/24 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.9%
1/34 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.4%
3/87 • Number of events 4 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Gastrointestinal disorders
Diarrhoea
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.3%
2/60 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.9%
1/34 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.8%
1/26 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Gastrointestinal disorders
Constipation
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
General disorders
Pain
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Infections and infestations
Urinary tract infection
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.0%
3/60 • Number of events 3 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.8%
1/26 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Infections and infestations
Upper respiratory tract infection
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Infections and infestations
Cellulitis
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Injury, poisoning and procedural complications
Accidental overdose
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
4.2%
1/24 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.9%
1/34 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.4%
3/87 • Number of events 4 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
23.5%
4/17 • Number of events 6 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Injury, poisoning and procedural complications
Hand fracture
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.7%
1/13 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Injury, poisoning and procedural complications
Laceration
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Injury, poisoning and procedural complications
Road traffic accident
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Investigations
Weight increased
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.0%
3/60 • Number of events 3 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.8%
1/26 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Investigations
Gamma-glutamyltransferase increased
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.3%
2/60 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
14.3%
2/14 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Investigations
Blood creatine phosphokinase increased
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.8%
1/26 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Investigations
Blood sodium decreased
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.3%
2/60 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Investigations
Hepatic enzyme increased
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
11.5%
3/26 • Number of events 3 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Investigations
Alanine aminotransferase increased
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
14.3%
2/14 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Investigations
Aspartate aminotransferase increased
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
14.3%
2/14 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Investigations
Blood alkaline phosphatase
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Metabolism and nutrition disorders
Hyponatraemia
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.0%
3/60 • Number of events 5 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.4%
2/27 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.7%
1/13 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Metabolism and nutrition disorders
Hypoglycaemia
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Musculoskeletal and connective tissue disorders
Muscle spasms
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.3%
2/60 • Number of events 3 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.7%
1/13 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Musculoskeletal and connective tissue disorders
Joint swelling
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
4.2%
1/24 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Musculoskeletal and connective tissue disorders
Myalgia
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/87 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Nervous system disorders
Headache
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.0%
3/60 • Number of events 4 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.9%
1/34 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.3%
2/87 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.8%
1/26 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Psychiatric disorders
Insomnia
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
3.8%
1/26 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Renal and urinary disorders
Dysuria
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Renal and urinary disorders
Renal impairment
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/14 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.7%
1/13 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/34 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.3%
2/87 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Vascular disorders
Hypertension
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.7%
1/60 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
7.1%
1/14 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.9%
1/34 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/17 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
Gastrointestinal disorders
Vomiting
0.00%
0/531 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/60 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/27 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/24 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
14.3%
2/14 • Number of events 2 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/13 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
2.9%
1/34 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
1.1%
1/87 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
0.00%
0/26 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.
5.9%
1/17 • Number of events 1 • Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.
The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.

Additional Information

Global Clinical Compliance

Ferring Pharmaceuticals

Phone: -

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: OTHER